The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Nontraditional risk factors, particularly migraine with aura, play a major role in patients under 50 years old.

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

This month: shorter recovery after TAVI, Down syndrome CV insights, the benefits of brisker walking, and more.

For all the different subpopulations, having a CAC score > 100 strongly predicted risk of CV death (P < 0.007). Yet the ...

Numerous components beyond length of sleep have important ties to cardiometabolic disease and related risk factors.